CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 112 enrolled
Drug / intervention
remimazolam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06093971
NCT06093971N/ACompleted
CompareCT.gov

Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot-assisted Laparoscopic Prostatectomy: A Randomized Controlled Study

Yonsei University·interventional·Posted Oct 23, 2023·Updated Dec 12, 2024

In Brief

A clinical study evaluating remimazolam and Propofol for Prostate Tumor. Completed, enrolled 112 participants across 1 site.

Detailed Summary

The investigators conduct a random assignment into either the remimazolam group or the propofol group. Depending on the group assignment, either remimazolam (0.2 mg/kg) or propofol (1.0 mg/kg) is administered. If necessary, additional doses of remimazolam (0.1 mg/kg) or propofol (0.5 mg/kg) are given. The standard anesthesia procedure of our institution is followed, and blood pressure data recorded during the surgery is analyzed (mean arterial pressure \<65mmHg is defined as hypotension).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Tumor
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedOct 23, 2023
Enrollment StartNov 17, 2023
Primary CompletionOct 22, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.7 years ago

Interventions

remimazolamdrug

Remimazolam is administered for anesthesia induction.

Propofoldrug

Propofol is administered for anesthesia induction.